title: HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population.
abstract: BACKGROUND
  With varied immunohistochemistry scoring criteria and patient cohorts, HER2-positivity rates in gastric cancer (GC) and gastroesophageal junction (GEJ) adenocarcinoma have been reported with a wide range. Recently standardized scoring criteria for GC and GEJ cancer has been established and recommended. In this study, the frequency of HER2 expression and the relationship between HER2 expression and clinicopathological features were examined in a large cohort of Chinese GC and GEJ cancer patients.
  
  
  METHODS
  A total of 1463 patients, including 929 primary GCs and 534 primary GEJ adenocarcinomas, was retrospectively analyzed for HER2 overexpression by immunohistochemistry (IHC). Fluorescence in situ hybridization (FISH) analysis was used in 308 GCs and GEJ adenocarcinoma cases to assess HER2 gene amplification.
  
  
  RESULTS
  HER2 overexpression (3+) was detected in 9.8% of carcinomas and more frequently observed in GEJ cancer cases, in the intestinal type, and in the well or moderately differentiated type (P=0.003, 0.000, and 0.000, respectively). HER2 equivocal (2+) was detected in 14.4% of cases. As for the 308 cases analyzed by FISH, 39 (of 40, 97.5%) IHC 3+ cases, 11 (of 38, 28.9%) IHC 2+ cases, and 3 (of 230, 1.3%) IHC 1+/0 cases showed HER2 gene amplification. A high concordance rate (98.5%) between IHC and FISH was demonstrated.
  
  
  CONCLUSIONS
  Approximately 10% of Chinese patients with primary GC and GEJ adenocarcinoma were HER2-positive on IHC. HER2 overexpression was associated with GEJ site, intestinal cancer subtype, and well or moderately differentiated carcinomas.
  The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1935951199941072.
authors: Department of Pathology, Cancer Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, China.
authors: Ling
authors: L
authors: Shan
authors: Jianming
authors: J
authors: Ying
authors: Ning
authors: N
authors: Lu
mesh_terms: D000230:Adenocarcinoma / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D044466:Asian People / Q000235:genetics*; D004943:Esophagogastric Junction / Q000378:metabolism* / Q000473:pathology; D005260:Female; D005784:Gene Amplification / Q000235:genetics; D015972:Gene Expression Regulation, Neoplastic / Q000235:genetics*; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods; D008297:Male; D008875:Middle Aged; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics / Q000378:metabolism*; D012189:Retrospective Studies; D013274:Stomach Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D055815:Young Adult
chemical_list: D018719:Erb-b2 Receptor Tyrosine Kinases
references: Diagn Pathol. 2006 May 11;1:5
references: 16759358
references: J Clin Oncol. 2006 May 10;24(14):2137-50
references: 16682732
references: Diagn Pathol. 2012 May 30;7:60
references: 22647525
references: Zhonghua Bing Li Xue Za Zhi. 2011 May;40(5):296-9
references: 21756821
references: Gastric Cancer. 2013 Jan;16(1):84-93
references: 22410801
references: Hum Pathol. 2009 Jun;40(6):769-77
references: 19269014
references: Mol Cytogenet. 2011 Jun 20;4(1):14
references: 21689422
references: J Cancer Res Clin Oncol. 2009 Oct;135(10):1331-9
references: 19337752
references: N Engl J Med. 2001 Mar 15;344(11):783-92
references: 11248153
references: Jpn J Clin Oncol. 2011 May;41(5):663-5
references: 21335337
references: Breast Cancer Res Treat. 2013 Feb;138(1):99-108
references: 23420271
references: Pathol Int. 2012 Nov;62(11):728-34
references: 23121603
references: Lancet. 2010 Aug 28;376(9742):687-97
references: 20728210
references: Histopathology. 2008 Jun;52(7):797-805
references: 18422971
references: Int J Cancer. 2012 Jun 15;130(12):2845-56
references: 21780108
references: Dis Esophagus. 2013 Apr;26(3):299-304
references: 22676551
references: Ann Surg Oncol. 2011 Oct;18(10):2833-40
references: 21468783
references: Onkologie. 2011;34(11):621-4
references: 22104159
references: Science. 1987 Jan 9;235(4785):177-82
references: 3798106
references: Clin Transl Oncol. 2011 Mar;13(3):179-84
references: 21421462
references: Arch Pathol Lab Med. 2011 Nov;135(11):1460-5
references: 22032573
references: Br J Cancer. 2011 Apr 26;104(9):1372-6
references: 21487407
references: Int J Epidemiol. 2000 Aug;29(4):645-54
references: 10922340
references: Diagn Pathol. 2008 Oct 22;3:41
references: 18945356
references: Cell Oncol. 2010;32(1-2):57-65
references: 20208134
references: J Clin Pathol. 2010 Sep;63(9):839-42
references: 20696687
references: Lancet. 2007 Jan 6;369(9555):29-36
references: 17208639
references: Onkologie. 2011;34(10):548-51
references: 21985855
references: World J Surg. 2009 Oct;33(10):2112-8
references: 19636613
references: Appl Immunohistochem Mol Morphol. 2012 Jan;20(1):13-24
references: 21617522
references: Virchows Arch. 2010 Sep;457(3):299-307
references: 20665045
references: Br J Cancer. 2009 Feb 10;100(3):487-93
references: 19156142
references: World J Gastroenterol. 2011 Mar 21;17(11):1501-6
references: 21472111